The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by BOSCH, R. F.
* Articles by ERLEY, C. M.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by BOSCH, R. F.
* Articles by ERLEY, C. M.
Related Collections
* Syndromes Secondary to General Medical Disorders
* Other Somatic Therapy
* Other Neuroleptics
Am J Psychiatry 157:304-305, February 2000
© 2000 American Psychiatric Association


Letter to the Editor

Intoxication With Olanzapine

RALPH F. BOSCH, M.D., ANDREAS BAUMBACH, M.D., MICHAEL BITZER, M.D., and CHRISTIANE M. ERLEY, M.D.
Tûbingen, Germany

To the Editor: Olanzapine is a new antipsychotic drug that is thought to have fewer side effects than other neuroleptics (14). There is one autopsy report (5) about a lethal overdose of olanzapine to date; however, there appear to be no reports about the clinical course and therapy of acute intoxication with olanzapine. We report the case of a 22-year-old man who was admitted to the hospital after he tried to commit suicide by tablet ingestion.

Mr. A suffered from schizophrenia and was currently being treated with olanzapine, 10 mg/day. He was not taking any other medications. Upon arrival in the emergency room, Mr. A was alert and oriented; he reported having ingested about 800 mg of olanzapine approximately 2.5 hours before his arrival. His vital signs at admission were stable; results of a physical examination and all routine laboratory tests were normal. Mr. A was admitted to the intensive care unit, and his condition was tracked with a Holter monitor. His olanzapine serum levels reached a maximum of 200 ng/ml, which is about 20 times higher than therapeutic levels of the drug (at a dose of 10 mg/day, normal serum levels are about 10 ng/ml). About 30 minutes later, he started to become progressively somnolent, a status that was interrupted by short periods of aggressive agitation. Because olanzapine has anticholinergic effects with a slowing of gastrointestinal passage, we performed a gastric lavage under protective intubation. In the gastric contents, multiple tablets could be seen. Further gastrointestinal decontamination was performed with active charcoal (10 g every 4 hours), sodium bicarbonate, and sodium sulfate.

Mr. A’s vital signs were stable at all times. His blood pressure ranged from 110/75 to 130/80 mm Hg; his heart rate was 100–120 bpm upon arrival and gradually declined to 60 bpm at discharge from the intensive care unit. Physostigmine, 2 mg i.v., administered in the acute phase, did not affect his heart rate, blood pressure, or breathing. Mr. A was extubated after 8 hours and completely alert and oriented after 10 hours. The observation period of 24 hours on the Holter monitor was without incident; no cardiac arrhythmia, neurological disorders, anticholinergic syndrome, laboratory test abnormalities, fever, or rhabdomyolysis were observed. After 24 hours, Mr. A was transferred to a psychiatric service for further observation.

In conclusion, olanzapine, approximately 800 mg taken for suicidal purposes, produced mainly sedative effects with only mild anticholinergic symptoms.

REFERENCES

  1. Gerlach J, Peacock L: New antipsychotics: the present status. Int Clin Pharmacol 1995; 10(suppl 3):39–48
  2. Baldwin DS, Montgomery SA: First clinical experience with olanzapine (LY 170053): results of an open-label safety and dose-ranging study in patients with schizophrenia. Int Clin Pharmacol 1995; 10:239–244
  3. Casey DE: Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996; 57(suppl 11):40–45
  4. Martin J, Gomez JC, Garcia-Bernardo E, Cuesta M, Alvarez E, Gurpegui M: Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. J Clin Psychiatry 1997; 58:479–483
  5. Elian AA: Fatal overdose of olanzapine. Forensic Sci Int 1998; 91:231–235




This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by BOSCH, R. F.
* Articles by ERLEY, C. M.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by BOSCH, R. F.
* Articles by ERLEY, C. M.
Related Collections
* Syndromes Secondary to General Medical Disorders
* Other Somatic Therapy
* Other Neuroleptics


Get information about faster international access.

Privacy Policy

Copyright © 2000 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org